| INTRODUCTION
CHARGE syndrome (CS) is a rare genetic disorder with variable occurrence of (C) coloboma, (H) heart defects, (A) atresia of choanae, (R) retardation of growth or development, (G) genital hypoplasia, and (E) ear abnormalities and deafness. The acronym was coined by Pagon, Zonana, and Graham (1982) but the syndrome was first reported by Hall (1979) and Hittner, Hirsch, Kreh, and Rudolph (1979) . Later, semicircular canal (SCC) anomalies, and arhinencephaly were found to be part of CS (Tellier et al. 1998; Amiel et al., 2001; Morimoto et al., 2006) . Clinical diagnostic criteria for CS were proposed in 1998 (Blake et al., 1998 ) and revised in 2005 : Verloes (2005 added SCC hypoplasia to the major criteria and proposed a classification of typical, partial, and atypical forms. Then, Blake and Prasad suggested that cleft palate may be used to replace choanal atresia when absent (Blake & Prasad, 2006) . Finally, in 2007 arhinencephaly or anosmia was added to the major features (Sanlaville & Verloes, 2007) (Table 1 ).
In 2004, the chromodomain helicase DNA binding protein 7 (CHD7) gene [OMIM *608892] was identified as the major gene involved in CS (Vissers et al., 2004) . In the literature, the detection rate of a pathogenic variant in the CHD7 gene varies from 67% to 90% Jongmans et al., 2006; Zentner, Layman, Martin, & Scacheri, 2010) . The elongation factor Tu GTP binding domain-containing 2 (EFTUD2) gene has been involved in some cases (Lehalle et al., 2014) .
In 2004, the chromodomain helicase DNA binding protein 7 (CHD7) gene [OMIM *608892] was identified as the major gene involved in CS. In the literature, the detection rate of a pathogenic variant in the CHD7 gene varies from 67% to 90%.
The aim of this study was first to describe phenotype and genotype of a large cohort of 119 French patients with CS, selected on the basis of their phenotype. The second aim was to search for correlations between the three clinical phenotypes (typical, partial and atypical, based on the Verloes criteria, updated by Blake and Sanlaville) , and the molecular anomalies of CHD7, mainly to search for differences between patients with or without CHD7 mutation in these different groups.
| PATIENTS AND METHODS
We conducted a national study of the phenotypes and genotypes of individuals with CS of all ages who were patients of developmental anomaly expert centers in France. Selected clinical diagnostic criteria were from Verloes (2005) updated by Blake & Prasad (2006) and Sanlaville & Verloes (2007) (Table 1) . Inclusion criteria of the study were a clinical CS according to our criteria, the patient's or his parents' consents for the study and genetic analyses. As our study took place before the publication of Hale, Niederriter, Green, and Martin in 2016, which introduced pathogenic CHD7 variants as a diagnosis criteria, we did not take this criteria into account for inclusion. Patients without selected clinical criteria of CS, those who refused to participate in the study, or whose parents refused genetic analyses were excluded. We asked all geneticists of the designated developmental anomaly centers to include as many patients fulfilling these criteria as possible, whatever their age.
These could be individuals who presented to the center as new patients or existing patients who were contacted back in the context of the study. In total, 125 patients were included from 33
French university hospitals after medical examination by a clinical geneticist between February 2012 and April 2015. Clinical and molecular data were collected by online web-based questionnaire. All information required by the protocol was recorded by investigators in an electronic case report form developed for the study using Captur System software (Clinsight). The questionnaire was developed by a group of geneticists and pediatricians with special concerns in the syndrome. It consisted of multiple choice questions and clarifications could be provided through a written text. Answers to each item were not mandatory.
Geneticists described their detailed clinical examination and, when possible, patients underwent full ophthalmologic examination including funduscopy, audiometry, temporal bone CT scan, gonadotropin and thyroid-stimulating hormone analysis, stimulation tests of growth hormone (GH), follow-up of pubertal development when relevant, and brain and olfactory-bulb MRI.
The data could be extracted from the patient's file if the patient had had these exams before the time of inclusion.
Results of karyotype, comparative genomic hybridization (CGH)
array, and fluorescent in situ hybridization for the 22q11.2 deletion were recorded. All patients underwent CHD7 sequencing as previously described (Bilan et al., 2012; Sanlaville et al., 2006) and MLPA was performed to exclude exon deletions. Genetic analyses could have been performed before the study in some cases and completed after inclusion if necessary. In total, 125 patients were screened. CHD7 NM_017780.2 and NG_007009.1 were used for nucleotide reference and exon numbering, respectively. Pathogenic CHD7 variants were classified by their expected impact on the protein. To investigate the potential impact on the splicing mechanism, all intronic and missense pathogenic variants were studied by using Human splicing finder software (http://www.umd. be/HSF3/). In some cases, minigene assays were used to clarify the impact on splicing efficiency. We used Polyphen 2.0 (http://genetics. bwh.harvard.edu/pph2/) to study the pathogenicity of variants, and the de novo origin was taken into account. We systematically queried the CHD7 database (https://molgenis51.gcc.rug.nl/) to determine whether variants had been described and predicted as pathogenic. CS patients described in this study and their corresponding variants were submitted in the CHD7 database (https:// molgenis51.gcc.rug.nl/). Samples for patients with no identified pathogenic CHD7 variant underwent sequencing for EFTUD2 (and eventually HOXA1, TBX22, FOXE1, TXNL4A).
Statistical analyses involved use of StatView software (SAS, Inc., Cary, NC) and because we could not obtain information for all items for each patient, the given percentages are the number of patients with a particular feature divided by the number of patients with information about the feature. For example, it was not ethically acceptable to LEGENDRE ET AL.
| 419 perform brain MRI without direct medical benefit and that sometimes requires general anesthesia for adult patients with a long-term diagnosis of CS.
The persons legally in charge of each patient gave their informed consent for the research. The ethical committee of our institution approved the project.
| RESULTS
In total, 125 patients were submitted for the study and screened for CHD7 mutations. Six patients were excluded because they did not fulfill the inclusion criteria (i.e., less than 2 major criteria or less than 1 major and 3 minor criteria), although three had a pathogenic CHD7 variant. One young female with intellectual disability, hypoplastic corpus callosum, aortic valve dysplasia, retarded growth, and facial palsy was suspected to have CS because of evocative dysmorphy, but she had neither coloboma, nor choanal atresia, nor olfactorybulb defect nor hypoplasia of the SCCs. Another newborn did not undergo all the necessary exams because of his young age.
Information regarding phenotype of the last case with a CHD7 mutation, and the three others (one with a pathogenic EFTUD2 variant) were unavailable.
Finally, we describe a series of 119 patients with CS (62 females; mean age 11 ± 10 years) in terms of the diagnostic criteria we defined.
Data for three patients were included after they died. Clinical and genetic data are reported in Table 2 . A pathogenic CHD7 variant was identified in 93/118 patients (79%).
Overall, 107/119 individuals (90%) had typical CS, and 12 (10%) had atypical CS. No partial form was identified. All cases were sporadic except for three familial cases: two cases of transmission from a parent with typical CS to a child, with a pathogenic CHD7 variant in one, and one case of suspected germ line mosaicism in one parent of two affected children (both parents were healthy and did not bear the pathogenic variant of their children).
| Monitoring of pregnancies and data at birth
During pregnancy, anomalies were detected in 46.6% (55/118) of cases. Nuchal translucency measurement was increased in four cases with a pathogenic CHD7 variant. Most anomalies were detected during the second trimester and were isolated in 21/35 cases. The most frequent features were intra-uterine growth retardation (IUGR) (fetal biometry <3th percentile) (13 cases), heart defects (12 cases), cleft lip and/or palate (7 cases), and polyhydramnios (6 cases). For 15 cases, an anomaly was identified during the third trimester and was a hydramnios in 11 cases, a heart defect in 2 cases, an IUGR in 1 case, and a urogenital malformation in one case.
The mean weeks' gestation at birth was 36.6 ± 2.2. The mean weight at birth was 0.6 SD (±1.1 SD) below the mean and mean length 1.3 SD (±1.2 SD) below the mean for the term of delivery. Overall, 29 patients (26%) had IUGR, and 4 (4%) had a head circumference below −2 SD of normal and 7 (7%) above +2 SD of normal. The mean Apgar score at 10 min was 7.7 for patients with a truncating pathogenic variant and 10 for patients with a non-truncating pathogenic variant (p = 0.036).
| Clinical results
Results are detailed in Table 2 and summarized in Table 3 . Differences between patients with or without variant in CHD7 gene are given in Verloes (2005) updated by Blake (2006) and Sanlaville & Verloes (2007) and by Hale (2016) Verloes (2005) updated by Blake (2006) and Sanlaville (2007) Hale ( Minor criteria -Cranial nerves VII to XII palsy; -Hypothalamo-hypophyseal dysfunction; -External-or middle-ear anomalies; -Heart defects or esophageal anomalies; -Intellectual disability -Cranial nerve dysfunction including hearing loss; -Dysphagia/feeding difficulties; -Structural brain anomalies; -Developmental delay/intellectual disabilities/autism; -Hypothalamo-hypophyseal dysfunction (gonadotropin or growth hormone deficiency) and genital anomalies; -Heart or esophagus malformation; -Renal anomalies; -Skeletal/limb anomalies Typical: 3 major or 2 major + 2 minor criteria; Partial: 2 major + 1 minor criteria; Atypical: 2 major + 0 minor or 1 major + 3 minor criteria 2 major + any number of minor criteria 113) of patients, 97% (86/89) of CHD7-positive patients, mostly bilateral (77/82 cases; 94%), of variable severity. Bilateral and 
| Craniofacial dysmorphism
The typical shape of ears (asymmetric square ears with a triangular concha and without an earlobe) was the most frequent feature (87% 
| Heart/oesophageal defects
Classifying the diagnostic criteria, Sanlaville (2007) proposed to combine these two different defects into one minor diagnostic criterion as a malformation of mediastinal organs (heart, esophagus).
A congenital heart defect was found in 65% (76/117) of patients; showed an anomalous pulmonary venous drainage, one aortic arch anomalies, two a right-sided aortic arch and one dextrocardia.
Esophageal defects occurred in 20% (21/107) of patients; 24%
(20/84) of CHD7-positive patients, mostly esophageal atresia (50%). In all, 72% (75/104) had gastroesophageal reflux disease.
Finally, 75% (86/115) of patients had heart disease or esophageal defects. 
| Ocular defects

| Intellectual disabilities
Intellectual disabilities were found in 66% (63/96) of patients; 62%
(48/77) of CHD7-positive patients. This item was estimated by the clinicians who included patients, without details. Assessing the disabilities in these patients who have two sensorial defects, deafness and visual impairment, is difficult. Another study is evaluating this item.
When the condition was known, all patients had delayed motor milestones.
| Other clinical features
Mean height, weight and head circumference were −1.7 SD (±1.6), Table 4 . No item significantly discriminated the groups.
Hearing loss and SCC anomalies were present in almost all patients with a pathogenic CHD7 variant (97-99%, respectively) versus 81-85% in patients without a CHD7 variant.
| Molecular analysis
Overall, 98/119 patients had a karyotype, which was normal in 88 cases.
One patient with a pathogenic CHD7 variant had a chromosomal inversion, inv(7)(p15.2q33) (and a normal CGH array), and the karyotype result was not mentioned for 9 patients. The 22q11.2 deletion was excluded in 62 patients. In total, 35/100 patients without an identified Pathogenic variants are summarized in Figure 2 and Figure 3 ).
| DISCUSSION
For half of our series of CS, anomalies were detected during pregnancy, mainly heart defects and cleft lip or palate, which are not specific features. This finding agrees with the study of Busa et al. (2016) who, in a series of 12 children with a diagnosis of CS in the first 3 months of life and a pathogenic CHD7 variant, found 58% of pregnancies complicated by the identification of isolated or multiple congenital anomalies.
Such circumstances should lead to propose a systematic careful prenatal US examination to identify typical external ears and/or SCC anomalies which is possible around the 20-22th weeks of gestation.
When the diagnosis is highly suspected, fetal brain MRI, feasible from the 28th week of gestation, and molecular analysis of CHD7 can be proposed to confirm the diagnosis.
| Diagnostic criteria
As our study took place before the publication of Hale et al. in 2016, which introduced pathogenic CHD7 variants as a diagnosis criteria, we did not take this criteria into account for inclusion of our patients. We chose to include patients on the basis of clinical data according to Verloes (2005) classification, updated by Blake et al. (2006) and Sanlaville et al. (2006) . In this cohort of 119 patients, we did not find any partial form of CS (i.e., 2 major and 1 minor criteria). 90% had a typical FIGURE 2 Pathogenic CHD7 variants in CHARGE syndrome (12), we could not statistically compare the two groups of typical CS form (3 major, or 2 major and 2 minor criteria) and atypical form (2 major, or 1 major and 3 minor criteria). Three patients were excluded because they lacked clinical criteria, but because the clinical practitioners suspected the diagnosis mainly on dysmorphic features, these patients were found, after inclusion, to have a pathogenic CHD7 variant. Recently, Hale et al. (2016) reported a series of 28 patients including one with atypical presentation and a pathogenic CHD7 variant and proposed to broaden the diagnostic criteria, adding a pathogenic CHD7 variant as a major criterion. If we had adopted this classification, these three patients would not have been excluded from our cohort.
As our study took place before the publication of Hale et al. in 2016 , which introduced pathogenic CHD7 variants as a diagnosis criteria, we did not take this criteria into account for inclusion of our patients. We chose to include patients on the basis of clinical data according to Verloes (2005) classification, updated by Blake et al. (2006) and Sanlaville et al. (2006) Regarding major and minor criteria, our results confirm that SCC hypoplasia/agenesis and arhinencephaly/anosmia, present in 95% and 80% of patients, respectively, are major features of the syndrome. In CNS, central nervous system; SCC, semicircular canals. The given percentages are the number of patients with a particular feature divided by the number of patients with information about the feature.
FIGURE 3 Type of mutations in CHARGE syndrome. Chr, chromosomal anomaly; CS, CHARGE syndrome our series, we had adults with a diagnosis of CS for a long time, who did not undergo cerebral MRI but had anosmia. Because arhinencephaly or absent olfactory bulbs or tracts are more objective criteria than is anosmia, these features must be checked with a cerebral MRI in young patients as soon as a CS diagnosis is suspected. This item, absent of the Hale's classification, should be kept as a criteria of diagnosis, even if less specific than SCC hypoplasia/agenesis. Coloboma was present in 73% of our patients, thereby corroborating it as a major sign of the syndrome. Bilateral and asymmetric external-ear anomalies were present in 87% of our patients and the middle ear was abnormal in only 38%. In the Verloes' classification, external-ear anomalies were considered a minor sign, but we agree with Hale that they should be considered a major sign, especially in atypical forms, for which these are often the first feature that suggests the diagnosis of CS. Choanal atresia was found in only 43% of patients, and so cannot be considered alone as a major sign. In 2006, Blake and Prasad proposed to associate isolated cleft palate (i.e., not associated with choanal atresia in a given patient) with choanal atresia and consider the item "choanal atresia and/or cleft palate" as a major sign (Blake & Prasad, 2006) . In our cohort, 56% of patients had one or both of these features.
Finally, 72% of our patients had hypogonadotrophic hypogonadism (HH). All patients did not have a biological analysis to ascertain HH, and this feature is often under-diagnosed in girls, because underdevelopment of external genitalia cannot be seen. For patients with a biological analysis, nearly 90% had HH. Recently, HH and agenesis of the uterus and ovaries was reported in a girl with CS due to a deletion of the CHD7 gene (Reynaert et al., 2016) . HH should be searched in patients in the first months of life if CS is suspected, because it can be treated at expected pubertal age, but biological diagnosis is not possible between age 6 months and puberty. Regarding this result of 90% of HH in CS patients, we suggest this item could be considered as a major criteria of the syndrome, even if not specific.
Dysmorphic traits of the face should be better considered for diagnosis of CS. A square-shaped face was found in 81% of our patients.
| Molecular analysis
In total, 79% (93/118) of patients had a pathogenic CHD7 variant, 83%
with a typical phenotype and 58% an atypical one. In 2010, Zentner et al., reviewing 379 cases of CS, found that 67% were CHD7 mutationpositive, whereas 33% were mutation-negative. Then, identification of intragenic deletion by MLPA identified other CHD7 mutation positive cases. Jongmans et al. (2006) found that mutation detection rate rises above 90% if only those CHARGE patients who met the clinical diagnostic criteria of Blake et al. (1998 ) and/or Verloes (2005 are taken into account. We have no explanation why the detection rate is lower in our study, while Verloes' criteria were taken into account. In our cohort, all patients underwent CHD7 sequencing and MLPA. In total, 79% (93/118) of patients had a pathogenic CHD7 variant, 83% with a typical phenotype and 58% an atypical one.
Among the 79 different pathogenic variants carried by our patients, 8 were previously described in other patients and 72 (90%) were novel. These results confirm that most of mutations of CDH7 gene are private ones.
Regarding the atypical phenotype, about the half (7/12) had a pathogenic truncating CHD7 variant. We would have expected less severe mutations. Therefore, we could not conclude to a phenotypegenotype correlation.
Two of our patients had a holoprosencephaly. It is of interest that one of them had a mutation in CHD7 (c.2504_2508delATCTT). This malformation had never been reported before in CS patients with a mutation in CHD7. In the other patient, no mutation was identified.
Unlike splice pathogenic variants (30% in our series vs. 11% in the literature), nonsense (29%) and missense (5%) pathogenic variants were less frequent in our cohort than previously described (44% and 8%; Janssen et al. 2012) . Improvement in the interpretation of intronic or exonic variants, even when recurrent, probably improves the detection rate of pathogenic variants. In most cases, CS is due to CHD7
haploinsufficiency. Pathogenic variants lead to a transcript carrying a premature stop codon that will be eliminated by nonsense-mediated mRNA decay. These pathogenic variants are truncating. Some patients have missense pathogenic variants or splice pathogenic variants involving sensitive interpretation. Sequence defects lead to a functional or structural alteration of the protein. These pathogenic variants are usually predicted to be responsible for a less severe phenotype.
Predicting the impact of a splice pathogenic variant is difficult. Most are probably responsible for CHD7 haploinsufficiency and some may create an in-frame transcript. Depending on the pathogenic variant, the transcript is not generated by the cell or is an alternative transcript of the wild type. An active protein rate is thus variable, as was described by Lee et al. (2016) regarding the c.2443-2A>G pathogenic variant.
In our series, one patient had a locus deletion and typical CS.
Among seven patients reported with a deletion involving the CHD7 gene, two did not have CS in terms of Verloes' diagnostic criteria. This is a rare cause of CS that should be systematically searched when direct sequencing results for CHD7 are negative. With the current technology of next-generation sequencing, these deletions should not be missed.
| Comparison of features of patients with and without a pathogenic CHD7 variant
As was previously reported by (Zentner et al., 2010) and (Lalani et al., 2006) , the frequency of hearing loss and SCC defects was greater with than without a pathogenic CHD7 variant (p = 0.03 and p = 0.004, respectively).
However, we did not find a significant difference between the groups in choanal atresia, heart defect, coloboma, growth retardation, milestone delay or kidney defects, which was reported by Hale et al., 2016; Lalani et al. (2006); and Zentner et al. (2010) . Arhinencephaly, intellectual disability, heart defects and IUGR were more frequent without than with a pathogenic variant. Heart defects could be a selection bias in our cohort because they are frequent sign indicating consultation with a geneticist.
Pathogenic variants were more frequent with typical than atypical CS (83% vs. 58%), but the number of patients (10%, 12) with atypical CS was not sufficient to conclude. Clinical classification was established to predict the pathogenic CHD7 variant but remains imperfect perhaps due to missed deep intronic pathogenic variants or regulatory region defects or misinterpreting CHD7 variants. For example, deletion of a region upstream of the CHD7 START codon has been described (Pisaneschi et al., 2015) . Some of the patients in the non-mutating group were probably misclassified. EFTUD2 was found involved in patients with a CS diagnosis and a specific feature, microcephaly (Lehalle et al., 2014) .
| Comparison of patients with truncating or nontruncating pathogenic variants
We studied all clinical features and known or presumed prognostic factors and found no statistically significant difference regarding term at birth or Apgar score. The mean Apgar score at 10 min was 7.7 for patients with a truncating pathogenic variant and 10 with a non-truncating pathogenic variant (p = 0.036) probably due to the absence of bilateral choanal atresia in patients with a nontruncating pathogenic variant (33% of patients with a truncating pathogenic variant had choanal atresia). Heart defects, CNS anomalies, and cranial nerve defects were more frequent with truncating than non-truncating pathogenic variants. This finding, expected to impact the prognosis of the syndrome, is in agreement with Bergman et al. (2012) who showed that CHD7 missense mutations are, in general, associated with a milder phenotype than truncating mutations.
| Limitations of the study
As our study took place before the publication of Hale et al. in 2016, which introduced pathogenic CHD7 variants as a diagnosis criteria, we did not take this criteria into account for inclusion of our patients. If we had adopted this classification, three patients would not have been excluded from our cohort. Although our patients met Verloes' criteria for inclusion, our detection rate of mutations in the CHD7 gene in typical cases (83%) is lower than the one of 90% reported by Jongmans et al. (2006) . At the moment, WES is going on for our CHD7-negative patients, which should raise this rate. 
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